<DOC>
	<DOCNO>NCT01353534</DOCNO>
	<brief_summary>Groups 1 3 receive two vaccination Day 0 Day 21 . Group 1 receive 3.8µg A/H5N1 antigen formulate AS03 adjuvant , administer IM injection . Group 2 receive 15µg A/H5N1 IM alone . Group 3 also receive 15µg A/H5N1 antigen administer IM follow topical application VEP vaccination site . Group 4 receive single vaccination Day 0 30µg A/H5N1antigen IM , follow application VEP vaccination site . The VEP ( Vaccine Enhancement Patch ) contain 50 mcg LT ( heat-labile enterotoxin E. coli )</brief_summary>
	<brief_title>Open-label Study Assess Immunogenicity Safety Vaccine Enhancement Patch When Administered With 2 Doses H5N1 Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult male females 1849 year age ( inclusive ) sign Informed Consent Women postmenopausal surgically sterile must negative serum urine pregnancy test screen inclinic visit understand become pregnant duration study . Clinically significant laboratory abnormality screen abnormality physical examination know allergy component A/H5N1 antigen know egg protein allergy known allergy adhesives known coagulation disorder use anticoagulant medication within 30 day prior vaccination plan usage study period participate research involve investigational product within 30 day plan date vaccination plan participation study period donate received blood blood product plasma within three month plan date vaccination plan donation use study period receive planned receipt seasonal influenza vaccine study period receive licensed vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior plan date vaccination plan receipt license vaccine first 42 day study previous plan vaccination vaccine contain oil water emulsion adjuvant previous plan vaccination pandemic vaccine A/H5N1 previous prove contact A/H5N1 wild type virus ever receive investigational enterotoxigenic E. coli LT , LT ( R192G ) NasalFlu , Berna Biotech , Ltd . Ever receive cholera toxin vaccine Recent regular use oral , topical inject steroid medication within 30 day prior vaccination plan use study period . Use immunosuppressive systemic steroid medication include inhaled steroid within three month prior vaccination plan use study period Comorbid condition treatment immunosuppressive , include cancer , diabetes , endstage renal disease , determine Investigator positive serology HIV1 , HIV2 , HBsAg , HCV history severe atopy medical history acute chronic skin disease vaccination area active skin allergy sign acute skin infection , sunburn skin abnormality vaccination area include fungal infection , severe acne , active contact dermatitis , history keloid formation hirsute vaccination area artificial tan duration study include screen period visible tattoo mark vaccination area would prevent appropriate dermatologic monitoring vaccination site fever great equal 38.0°C time plan vaccination suspicion recent history alcohol substance abuse woman pregnant breastfeed acute illness screen time plan vaccination ever serious reaction prior influenza vaccination develop neurological disorder follow previous influenza vaccination acute evolve neurological disorder employee investigational site sponsor history employment bird poultry industry considerable exposure bird</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Immunogenicity Safety</keyword>
</DOC>